Preparation for the global Phase 2 trial of NS-089/NCNP-02
First written in FY2023. 4 of 6 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「• The global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy, has been ongoing since February 2024.」
The global Phase 2 trial of NS-089/NCNP-02, launched in February 2024, remains ongoing. - FY2024AdvancedAnnual report
「The global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy, was launched in February 2024.」
NS-089/NCNP-02 progressed from the preparation stage for the global Phase 2 trial to the trial launch stage in February 2024. - FY2024-Q3RestatedAnnual report
「• Preparation is underway for the global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 2 trial of NS-089/NCNP-02 was disclosed again. - FY2024-Q2RestatedAnnual report
「• Preparation is underway for the global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 2 trial of NS-089/NCNP-02 was disclosed again. - FY2024-Q1RestatedAnnual report
「• Preparation is underway for the global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 2 trial of NS-089/NCNP-02 was disclosed again. - FY2023First statedAnnual report
「Preparation is underway for the global Phase 2 trial of NS-089/NCNP-02 (generic name: brogidirsen), a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 2 trial of NS-089/NCNP-02 for Duchenne muscular dystrophy was disclosed for the first time.